CLOCK and glioblastoma: This strategy has been applied only recently to treat CNS tumors because a differential response to the proteasome inhibitor Bortezomib was shown in a murine model [21] and that TMZ administration in human and murine GBM cells in culture is dependent on clock gene expression [22].